Clinical trial
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
NCT00328120 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00328120 |
|---|---|
| Title | Faslodex 500mg Multiple Dose Tolerability Study in BC Patients |
| Official title | An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 20 |
| Start date | Apr 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Jun 1, 2010 |
| First posted | May 19, 2006 |
| Last update posted | Nov 17, 2010 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: